Definium Therapeutics

It’s been a big year for the Definium team, and today we announced our Q3 2026 financial results and business highlights. From pivotal study milestones to strategic progress across our commercial development plans, we’re advancing efforts toward raising the bar on mental health treatment as we anticipate an NDA filing in 1H 2027.

Please see here for details: bit.ly/4eWinCe

#InvestorRelations #MentalHealth #HealthcareInnovation #Neuroscience #GAD #MDD #PTSD

Attending the Neuroscience Education Institute Congress this week? So is #TeamDefinium. For the very first time on a medical congress stage, we will be sharing a combined presentation of DT120 clinical program to date including positive topline data from Panorama, Emerge and Voyage Phase 3 studies plus a new compilation of Phase 3 safety data – demonstrating the breadth of our DT120 clinical program.

Make sure to visit our booth #1100 to connect with our team and learn more about our research in generalized anxiety disorder (GAD) and major depressive disorder (MDD).

Learn more about our congress presence here: bit.ly/4A2upC4

#DefiniumTherapeutics #NEICongress #MentalHealth #Neuroscience #GAD #MDD #ClinicalTrials

As we round out a year marked by significant clinical and corporate momentum, Definium is taking the stage to share what’s next.

In the coming weeks, our leadership team will present at multiple investor conferences, to discuss our path toward potential commercialization and corporate strategy.

We look forward to connecting with peers and investors across the sector on what this year’s progress means for the future of psychiatric care, and how we are working to fundamentally raise the bar for people living with mental health disorders.

Read the full announcement for presentation schedules and webcast links: bit.ly/4BEUDfN

#InvestorRelations #MentalHealth #HealthcareInnovation #Neuroscience #GAD #MDD

At the @CNSSummit, our Chief Medical Officer, Dan Karlin, is joining industry peers to discuss modernizing clinical development across neuroscience and mental health. Open scientific dialogue is essential to driving better future outcomes for patients.

#HealthcareInnovation #Neuroscience #DefiniumTherapeutics #MentalHealth

With three positive topline Phase 3 readouts under our belt and a year of tremendous momentum, we look forward to reporting our third quarter 2026 financial results and recent business updates. Learn more here: bit.ly/4e3pZT9